191407-39-3

Usage

Uses

Used in Organic Synthesis:
1-((4-(3-IODOPROPYL)PHENOXY)METHYL)BENZENE is used as a starting material or intermediate for [application reason] the synthesis of various organic compounds. Its unique structure allows for a range of chemical reactions and functionalization, enabling the creation of diverse derivatives with different properties and uses.
Used in Pharmaceutical Industry:
1-((4-(3-IODOPROPYL)PHENOXY)METHYL)BENZENE is used as a key component in the development of new drugs and compounds for [application reason] its potential to be modified and functionalized, leading to the creation of pharmaceuticals with specific therapeutic properties.
Used in Chemical Research:
1-((4-(3-IODOPROPYL)PHENOXY)METHYL)BENZENE is used as a research tool for [application reason] studying its chemical properties, reactivity, and potential applications in various fields, including material science and drug discovery.

Upstream product

• 61440-41-3 1-benzyloxy-4-[3-(methanesulphonyloxy)propyl]-benzene 
• 61440-45-7 3-[4-(benzyloxy)phenyl]propan-1-ol 

Downstream Products

• 1333170-21-0 (6S)-6-{3-[4-benzyloxyphenyl]propoxy}-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine 
• 339220-97-2 (2S,3R)-2-[3-(4-Benzyloxy-phenyl)-propyl]-3-{(S)-1-methoxycarbonyl-2-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-ethylcarbamoyl}-5-methyl-hexanoic acid tert-butyl ester 
• 339221-01-1 (2S,3R)-2-[3-(4-Benzyloxy-phenyl)-propyl]-5-methyl-3-{2-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-ethylcarbamoyl}-hexanoic acid tert-butyl ester 
• 339220-96-1 (2S,3R)-2-[3-(4-Benzyloxy-phenyl)-propyl]-3-[(S)-2-(4-hydroxy-3-iodo-phenyl)-1-methoxycarbonyl-ethylcarbamoyl]-5-methyl-hexanoic acid tert-butyl ester 
• 339220-98-3 (2S,3R)-2-[3-(4-Hydroxy-phenyl)-propyl]-3-{(S)-1-methoxycarbonyl-2-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-ethylcarbamoyl}-5-methyl-hexanoic acid tert-butyl ester 
• 339221-08-8 C₃₂H₄₆BNO₉ 
• 339220-94-9 (2S,3R)-2-[3-(4-Benzyloxy-phenyl)-propyl]-3-[(S)-2-(4-iodo-phenyl)-1-methoxycarbonyl-ethylcarbamoyl]-5-methyl-hexanoic acid tert-butyl ester 
• 339221-04-4 C₃₁H₄₄BNO₈ 
• 339220-99-4 (2S,3R)-2-[3-(4-Hydroxy-phenyl)-propyl]-5-methyl-3-{2-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-ethylcarbamoyl}-hexanoic acid tert-butyl ester 
• 339220-95-0 (2S,3R)-2-[3-(4-Benzyloxy-phenyl)-propyl]-3-[2-(4-bromo-phenyl)-ethylcarbamoyl]-5-methyl-hexanoic acid tert-butyl ester 
• 339221-06-6 C₂₉H₄₂BNO₆ 
• 339221-03-3 (2S,3R)-2-[3-(4-Benzyloxy-phenyl)-propyl]-3-{(S)-1-methoxycarbonyl-2-[4-methoxy-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-ethylcarbamoyl}-5-methyl-hexanoic acid tert-butyl ester 
• 339221-00-0 (2S,3R)-2-[3-(4-Hydroxy-phenyl)-propyl]-3-{(S)-1-methoxycarbonyl-2-[4-methoxy-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-ethylcarbamoyl}-5-methyl-hexanoic acid tert-butyl ester 
• 339221-02-2 (2S,3R)-2-[3-(4-Benzyloxy-phenyl)-propyl]-3-[(S)-2-(3-iodo-4-methoxy-phenyl)-1-methoxycarbonyl-ethylcarbamoyl]-5-methyl-hexanoic acid tert-butyl ester 

Relevant academic research and scientific papers

Synthesis and structure-activity relationships of varied ether linker analogues of the antitubercular drug (6 S)-2-nitro-6-{[4-(trifluoromethoxy) benzyl]oxy}-6,7-dihydro-5 H -imidazo[2,1- b ][1,3]oxazine (PA-824)

New analogues of antitubercular drug PA-824 were synthesized, featuring alternative side chain ether linkers of varying size and flexibility, seeking drug candidates with enhanced metabolic stability and high efficacy. Both α-methyl substitution and removal of the benzylic methylene were broadly tolerated in vitro, with a biaryl example of the latter class exhibiting an 8-fold better efficacy than the parent drug in a mouse model of acute Mycobacterium tuberculosis infection and negligible fragmentation to an alcohol metabolite in liver microsomes. Extended linkers (notably propenyloxy, propynyloxy, and pentynyloxy) provided greater potencies against replicating M. tb (monoaryl analogues), with propynyl ethers being most effective under anaerobic (nonreplicating) conditions (mono/biaryl analogues). For benzyloxybenzyl and biaryl derivatives, aerobic activity was maximal with the original (OCH2) linker. One propynyloxy-linked compound displayed an 89-fold higher efficacy than the parent drug in the acute model, and it was slightly superior to antitubercular drug OPC-67683 in a chronic infection model.

ALKANOIC ACID DERIVATIVES AND THEIR THERAPEUTIC USE AS HDAC INHIBITORS

The invention related to alkanoic acid derivatives of Formula (IIa) and (IIb). These compounds of the invention were found to have activity as HDAC inhibitors.

AMINO ALCOHOL DERIVATIVE, ADDITION SALT THEREOF, AND IMMUNOSUPPRESSANT

An amino alcohol derivative represented by the following general formula (1) (for example, (±)-2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentane-1-ol) exhibits strong immunosuppressive effect while causing less side effects:

DIARYL ETHER DERIVATIVE, ADDITION SALT THEREOF, AND IMMUNOSUPPRESSANT

The present invention provides diaryl ether derivatives that exhibit significant immunosuppressive effects with less side effects. The diaryl derivatives of the present invention are represented by the following general formula (1): ???one example is 2-amino-2-[4-(3-benzyloxyphenoxy)-2-chlorophenyl)propyl-1,3-propanediol.

Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor α release in vitro and in vivo

To search for TNF-α (tumor necrosis factor α) converting enzyme (TACE) inhibitors, we designed a new class of macrocyclic hydroxamic acids by linking the P1 and P2′ residues of acyclic anti-succinate-based hydroxamic acids. A variety of residues including amide, carbamate, alkyl, sulfonamido, Boc-amino, and amino were found to be suitable P1 P1-P2′ linkers. With an N-methylamide at P3′, the 13-16-membered macrocycles prepared exhibited low micromolar activities in the inhibition of TNF-α release from LPS-stimulated human whole blood. Further elaboration in the P3′-P4′ area using the cyclophane and cyclic carbamate templates led to the identification of a number of potent analogues with IC50 values of ≤0.2 μM in whole blood assay (WBA). Although the P3′ area can accommodate a broad array of structurally diversified functional groups including polar residues, hydrophobic residues, and amino and carboxylic acid moieties, in both the cyclophane series and the cyclic carbamate series, a glycine residue at P3′ was identified as a critical structural component to achieve both good in vitro potency and good oral activity. With a glycine residue at P3′, an N-methylamide at P4′ provided the best cyclophane analogue, SL422 (WBA IC50 = 0.22 μM, LPS-mouse ED50 = 15 mg/kg, po), whereas a morpholinylamide at P4′ afforded the most potent and most orally active cyclic carbamate analogue, SP057 (WBAIC50 = 0.067 μM, LPS-mouse ED50 = 2.3 mg/kg, po). Further profiling for SL422 and SP057 showed that these macrocyclic compounds are potent TACE inhibitors, with Ki values of 12 and 4.2 nM in the porcine TACE assay, and are broad-spectrum MMP inhibitors. Pharmacokinetic studies in beagle dogs revealed that SL422 and SP057 are orally bioavailable, with oral bioavailabilities of 11% and 23%, respectively.